2025-04-01 2026-03-31 2026-03-31 false 10733586 Scars, Cosmetic And Aesthetic Reconstruction Limited 86220Specialists medical practice activities iso4217:GBP xbrli:pure 107335862025-04-01 107335862026-03-31 107335862025-04-01 2026-03-31 10733586bus:SmallEntities2025-04-01 2026-03-31 10733586bus:AuditExempt-NoAccountantsReport2025-04-01 2026-03-31 10733586bus:FullAccounts2025-04-01 2026-03-31 10733586core:WithinOneYear2026-03-31 10733586core:AfterOneYear2026-03-31 10733586core:WithinOneYear2025-04-01 2026-03-31 10733586core:AfterOneYear2025-04-01 2026-03-31 10733586core:CurrentFinancialInstruments2026-03-31 10733586core:Non-currentFinancialInstruments2026-03-31 10733586core:CurrentFinancialInstruments2025-04-01 2026-03-31 10733586core:Non-currentFinancialInstruments2025-04-01 2026-03-31 10733586core:LandBuildings2025-04-01 2026-03-31 10733586core:FurnitureFittings2025-04-01 2026-03-31 10733586core:OfficeEquipment2025-04-01 2026-03-31 10733586core:Vehicles2025-04-01 2026-03-31 10733586core:PlantMachinery2025-04-01 2026-03-31 10733586core:OtherPropertyPlantEquipment2025-04-01 2026-03-31 10733586core:LandBuildings2026-03-31 10733586core:PlantMachinery2026-03-31 10733586core:Vehicles2026-03-31 10733586core:FurnitureFittings2026-03-31 10733586core:OfficeEquipment2026-03-31 10733586core:OtherPropertyPlantEquipment2026-03-31 10733586core:Right-of-useAssets2025-04-01 2026-03-31 10733586core:Right-of-useAssets2026-03-31 10733586core:Goodwill2025-04-01 2026-03-31 10733586core:PatentsTrademarksLicencesConcessionsSimilar2025-04-01 2026-03-31 10733586core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-04-01 2026-03-31 10733586core:OtherResidualIntangibleAssets2025-04-01 2026-03-31 10733586core:Goodwill2026-03-31 10733586core:DevelopmentCostsCapitalisedDevelopmentExpenditure2026-03-31 10733586core:PatentsTrademarksLicencesConcessionsSimilar2026-03-31 10733586core:OtherResidualIntangibleAssets2026-03-31 10733586dpl:CostSales2025-04-01 2026-03-31 10733586dpl:AdministrativeExpenses2025-04-01 2026-03-31 10733586dpl:DistributionCosts2025-04-01 2026-03-3110733586core:ShareCapital2026-03-31 10733586core:SharePremium2026-03-31 10733586core:RevaluationReserve2026-03-31 10733586core:OtherReservesSubtotal2026-03-31 10733586core:ShareCapitalPreferenceShares2026-03-31 10733586core:CapitalRedemptionReserve2026-03-31 10733586core:OtherCapitalReserve2026-03-31 10733586core:RetainedEarningsAccumulatedLosses2026-03-3110733586core:ShareCapital2025-04-01 2026-03-31 10733586core:SharePremium2025-04-01 2026-03-31 10733586core:RevaluationReserve2025-04-01 2026-03-31 10733586core:OtherReservesSubtotal2025-04-01 2026-03-31 10733586core:RetainedEarningsAccumulatedLosses2025-04-01 2026-03-311073358612025-04-01 2026-03-31 1073358622025-04-01 2026-03-3110733586core:ShareCapital12025-04-01 2026-03-31 10733586core:ShareCapital22025-04-01 2026-03-3110733586core:SharePremium12025-04-01 2026-03-31 10733586core:SharePremium22025-04-01 2026-03-3110733586core:RevaluationReserve12025-04-01 2026-03-31 10733586core:RevaluationReserve22025-04-01 2026-03-3110733586core:RetainedEarningsAccumulatedLosses12025-04-01 2026-03-31 10733586core:RetainedEarningsAccumulatedLosses22025-04-01 2026-03-311073358612025-04-01 2026-03-3110733586core:Non-currentFinancialInstrumentscore:CostValuation2025-04-01 10733586core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2026-03-31 10733586core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2026-03-3110733586core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2026-03-31 10733586core:Non-currentFinancialInstrumentscore:TransfersIntoOrOutInvestmentsIncreaseDecreaseInInvestments2026-03-31 10733586core:Non-currentFinancialInstrumentscore:CostValuation2026-03-3110733586core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2025-04-01 10733586core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2026-03-31 10733586core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2026-03-31 10733586core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2026-03-31 10733586core:Non-currentFinancialInstrumentscore:FurtherSpecificIncreaseDecreaseInProvisionsForImpairmentInvestments1ComponentCorrespondingTotal2026-03-31 10733586core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2026-03-31 10733586core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2026-03-3110733586core:Non-currentFinancialInstruments2026-03-31 10733586core:Non-currentFinancialInstruments2025-03-31107335862024-04-01 107335862025-03-31 107335862024-04-01 2025-03-31 10733586core:WithinOneYear2025-03-31 10733586core:AfterOneYear2025-03-31 10733586core:CurrentFinancialInstruments2025-03-31 10733586core:Non-currentFinancialInstruments2025-03-31 10733586core:LandBuildings2025-03-31 10733586core:PlantMachinery2025-03-31 10733586core:Vehicles2025-03-31 10733586core:FurnitureFittings2025-03-31 10733586core:OfficeEquipment2025-03-31 10733586core:OtherPropertyPlantEquipment2025-03-31 10733586core:Right-of-useAssets2025-03-31 10733586core:Goodwill2025-03-31 10733586core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-03-31 10733586core:PatentsTrademarksLicencesConcessionsSimilar2025-03-31 10733586core:OtherResidualIntangibleAssets2025-03-31 10733586dpl:AdministrativeExpenses2024-04-01 2025-03-3110733586core:ShareCapital2025-03-31 10733586core:SharePremium2025-03-31 10733586core:RevaluationReserve2025-03-31 10733586core:OtherReservesSubtotal2025-03-31 10733586core:ShareCapitalPreferenceShares2025-03-31 10733586core:CapitalRedemptionReserve2025-03-31 10733586core:OtherCapitalReserve2025-03-31 10733586core:RetainedEarningsAccumulatedLosses2025-03-3110733586core:RetainedEarningsAccumulatedLosses2024-04-01 10733586core:ShareCapital2024-04-01 10733586core:SharePremium2024-04-01 10733586core:RevaluationReserve2024-04-01 10733586core:ShareCapital2024-04-01 2025-03-31 10733586core:SharePremium2024-04-01 2025-03-31 10733586core:RevaluationReserve2024-04-01 2025-03-31 10733586core:OtherReservesSubtotal2024-04-01 2025-03-31 10733586core:RetainedEarningsAccumulatedLosses2024-04-01 2025-03-311073358612024-04-01 2025-03-31 1073358622024-04-01 2025-03-3110733586core:ShareCapital12024-04-01 2025-03-31 10733586core:ShareCapital22024-04-01 2025-03-3110733586core:SharePremium12024-04-01 2025-03-31 10733586core:SharePremium22024-04-01 2025-03-3110733586core:RevaluationReserve12024-04-01 2025-03-31 10733586core:RevaluationReserve22024-04-01 2025-03-3110733586core:RetainedEarningsAccumulatedLosses12024-04-01 2025-03-31 10733586core:RetainedEarningsAccumulatedLosses22024-04-01 2025-03-3110733586bus:Director12025-04-01 2026-03-3110733586bus:PrivateLimitedCompanyLtd2025-04-01 2026-03-31
Scars, Cosmetic And Aesthetic Reconstruction Limited
Unaudited Financial Statements
for the year ended 31 March 2026
Company registration number 10733586
(England and Wales)

Company Information

For the year ended 31 March 2026
Director Ioannis Goutos

Registered office 17a Belgrave Court 36 Westferry Circus
London
E14 8RL

Registered number 10733586

Accountant CBA Services Limited
45 East Street
Blandford Forum
Dorset
DT11 7DX

Balance Sheet

As at 31 March 2026
Notes
2026
2025
£
£
£
£
Fixed assets
Tangible assets
4
13,850
17,728
13,850
17,728
Current assets
Debtors
5
64,308
63,736
Investments
291,872
-
Cash at bank and in hand
6
49,746
349,987
405,926
413,723
Creditors
Amounts falling due within one year
7
(237,626)
(166,239)
(237,626)
(166,239)
Net current assets (liabilities)
168,300
247,484
Total assets less current liabilities
182,150
265,212
Provisions for liabilities
8
(3,462)
(4,432)
Net assets (liabilities)
178,688
260,780
Capital and reserves
Called up share capital
100
100
Profit and loss account
178,588
260,680
Total equity
178,688
260,780

The company is a private company limited by shares and registered in England and Wales. It was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
The financial statements have been prepared in accordance with the special provisions applicable to companies subject to the small companies regime.
The directors have chosen to not file a copy of the company's profit and loss account under section 444 (5A) of the Companies Act 2006.

The financial statements were approved and authorised for issue by the director on 21 September 2026 and are signed on its behalf by:

Ioannis Goutos
Ioannis Goutos
Director

Company registration number 10733586

Notes to the Financial Statements

For the year ended 31 March 2026

1. Statutory information

The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The financial statements are presented in sterling and this is the functional currency of the company.

2. Accounting policies

2.1. Basis of preparation

The financial statements have been prepared in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.

The financial statements have been prepared under the historical cost convention in accordance with the Companies Act 2006.

2.2. Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.


Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.

2.3. Pensions

Defined contribution pension plan

The company operates a defined contribution pension plan for the benefit of its employees. Contributions are recognised as expenses as they become payable. Differences between contributions payable in the year and those actually paid are recognised as either prepayments or accruals in the balance sheet. The assets of the defined contribution pension scheme are held separately from those of the company in an independently administered fund.

2.4. Interest receivable

Interest income is recognised using the effective interest rate method.

2.5. Current taxation

Current tax is recognised in profit or loss, except for taxes related to revaluations of land and buildings which are recognised in other comprehensive income.


Current tax represents the amount of tax payable (receivable) in respect of taxable profit (loss) for the current, or past, reporting periods. Current tax is measured at the amount expected to be paid (recovered) using the tax rates and laws which have been enacted, or substantively enacted, by the balance sheet date. Where payments to HM Revenue and Customs exceed liabilities owed, an asset is recognised to the extent of the amount of tax recoverable.

2.6. Deferred tax

Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.

2.7. Tangible fixed assets and depreciation

All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Rate
Method
%
Plant and machinery
25
Reducing balance
Office and computer equipment
25
Straight-line

2.8. Investments

Investments in equity instruments that are publicly traded are measured at fair value, with changes in fair value recognised in the profit and loss.

2.9. Trade and other debtors

Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.

2.10. Trade and other creditors

Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.

2.11. Share capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.

3. Employees

The average number of employees during the year was 1 (2025: 1).

4. Tangible fixed assets

Plant and machinery
Office equipment
Total
£
£
£
Cost
At 1 April 2025
30,246
3,243
33,489
Additions
-
800
800
At 31 March 2026
30,246
4,043
34,289
Depreciation and impairment
At 1 April 2025
14,580
1,181
15,761
Charge for the period
3,916
762
4,678
At 31 March 2026
18,496
1,943
20,439
Net book value
At 31 March 2026
11,750
2,100
13,850
At 31 March 2025
15,666
2,062
17,728

5. Debtors

2026
2025
£
£
Trade debtors
28,519
28,624
Prepayments and accrued income
35,789
35,112
Total due within one year
64,308
63,736
Total due after one year
-
-
Total
64,308
63,736

6. Cash at bank and in hand

2026
2025
£
£
Cash at bank
49,746
349,987
Total
49,746
349,987

7. Creditors due within one year

2026
2025
£
£
Trade creditors
1,104
90
Other creditors
141
140
Directors loan account
1,281
1,281
Taxation and social security
183,617
132,388
Accruals and deferred income
51,483
32,340
Total
237,626
166,239

8. Provisions for liabilities

2026
2025
£
£
Deferred tax
3,462
4,432
Total
3,462
4,432

9. Deferred Tax

The deferred tax asset and provision consists of the following deferred tax liabilities/(assets):

2026
2025
£
£
Accelerated capital allowances
3,462
4,432
Net deferred tax liabilities/(assets)
3,462
4,432
Deferred tax liabilities
3,462
4,432
Net deferred tax liabilities/(assets)
3,462
4,432

The values of the deferred tax liabilities/(assets) at the balance sheet date have been calculated using the applicable rate when the asset is expected to be realised.